FMR1 and fragile X syndrome: Over the past few decades, treatments for challenging behaviors in FXS have typically involved pharmacological agents (e.g., antipsychotics, stimulants), as well as experimental pharmacotherapies targeted to the downstream effects of reduced FMRP [11].